OptimizeRx (NASDAQ:OPRX) Shareholders Have Endured a 83% Loss From Investing in the Stock Three Years Ago
Critical Insights From OptimizeRx Analyst Ratings: What You Need To Know
7 analysts have shared their evaluations of OptimizeRx (NASDAQ:OPRX) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table encapsulates their recent
JMP Securities Reiterates Market Outperform on OptimizeRx, Maintains $16 Price Target
JMP Securities analyst Constantine Davides reiterates OptimizeRx (NASDAQ:OPRX) with a Market Outperform and maintains $16 price target.
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $16
JMP Securities analyst Constantine Davides maintains $OptimizeRx(OPRX.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 23.6%
New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations
• 84% of Patients Arrive at Doctor Visits Underinformed• Underscores Growing Importance of HCP and DTC Alignment in Pharma Commercialization and Marketing Strategies• OPRX Closes First Combined HCP and DTC DAAP Marketing
OptimizeRx | 10-Q: Quarterly report
OptimizeRx Price Target Raised to $16.00/Share From $15.00 by JMP Securities
OptimizeRx Price Target Raised to $16.00/Share From $15.00 by JMP Securities
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersSINTX Techs (NASDAQ:SINT) stock moved upwards by 136.2% to $0.13 during Wednesday's regular session. The company's market cap stands at $15.9 million. The company's, Q1 earnings came out 2 days
OptimizeRx Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
OptimizeRx Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Expert Ratings For OptimizeRx
OptimizeRx (NASDAQ:OPRX) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below offers a condensed view of their re
OptimizeRx Is Maintained at Buy by Stifel
OptimizeRx Is Maintained at Buy by Stifel
Stifel Maintains Buy on OptimizeRx, Maintains $13 Price Target
Stifel analyst David Grossman maintains OptimizeRx with a Buy and maintains $13 price target.
OptimizeRx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 13.04% Stifel $13 → $13 Maintains Buy 04/16/2024 30.43% JMP Securities → $15 Reiterates Market
Stifel Nicolaus Reaffirms Their Buy Rating on OptimizeRx (OPRX)
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), PepGen Inc. (PEPG) and RegenXBio (RGNX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: OptimizeRx (OPRX), Immunocore Holdings (IMCR) and Acadia Healthcare (ACHC)
Earnings Call Summary | OptimizeRx(OPRX.US) Q1 2024 Earnings Conference
The following is a summary of the OptimizeRx Corporation (OPRX) Q1 2024 Earnings Call Transcript:Financial Performance:OptimizeRx reported Q1 2024 revenues of $19.7 million, a 51% increase year-over-y
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and OptimizeRx (OPRX)
OptimizeRx Corporation (OPRX) Q1 2024 Earnings Call Transcript
OptimizeRx Corporation (OPRX) Q1 2024 Earnings Call Transcript
OptimizeRx Expects FY24 Rev to Be at Least $100 M With Adj EBITDA of at Least $11 M
OptimizeRx Expects FY24 Rev to Be at Least $100 M With Adj EBITDA of at Least $11 M